Introduction to PolypDx™: Cancer prevention made

After having been with Metabolomic Technologies Inc. (MTI) for two months, I would like to provide my view on the company's lead product, PolypDx™.  

If you were asked which type of cancer is the deadliest, colorectal cancer might not be the first one to come to mind. However, colorectal cancer is the third most commonly diagnosed cancer and the second deadliest cancer in the United States. Thousands of patients are affected by colorectal cancer every year - this number increases exponentially when families are taken into account.

What if some of these deaths could be prevented with a simple test?

We at MTI, an Edmonton-based spin-out company, have developed PolypDx™, the first and only urine-based test that sensitively detects adenomatous polyps, the precursor for colorectal cancer.

PolypDx™ gives doctors a new tool in the fight against colorectal cancer. PolypDx™ detects patients at risk for colorectal cancer before the cancer develops. Additionally, the test is convenient and noninvasive for the patient - typically, colorectal cancer is tested using stool-based testing. Other than being a more inconvenient and unpleasant experience, stool-based testing often catches polyps once they’ve already progressed to the cancerous stage - meaning, it’s become too late for surgery alone to remove them.

Personally, I have family members who have delayed their screening for colorectal cancer. In fact, many patients at risk for colorectal cancer often opt out of getting tested simply because stool testing, is so unpleasant and inconvenient. A urine test, by contrast, is easier and more accessible for both patients and clinicians, meaning more patients in need of testing will agree to be tested. No patient should risk developing a preventable cancer due to fear of testing.

Help us prevent unnecessary colorectal cancer deaths. Learn more about PolypDx™ here.

 

Nicola McFarlane, MSc, MBA

Director of Business Development for US

Metabolomic Technologies Inc.